Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

Am J Cardiol. 1999 May 13;83(9B):25F-29F. doi: 10.1016/s0002-9149(99)00211-8.


The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk of cardiovascular disease events. Insulin resistance may lie at the heart of the metabolic syndrome. Elevated serum triglycerides commonly associate with insulin resistance and represent a valuable clinical marker of the metabolic syndrome. Abdominal obesity is a clinical marker for insulin resistance. The metabolic syndrome manifests 4 categories of abnormality: atherogenic dyslipidemia (elevated triglycerides, increased small low-density lipoproteins, and decreased high-density lipoproteins), increased blood pressure, elevated plasma glucose, and a prothrombotic state. Various therapeutic approaches for the patient with the metabolic syndrome should be implemented to decrease the risk of cardiovascular disease events. These interventions include decreasing obesity, increasing physical activity, and managing dyslipidemia; the latter may require the use of pharmacotherapy with cholesterol-lowering and triglyceride-lowering drugs.

Publication types

  • Review

MeSH terms

  • Exercise
  • Female
  • Humans
  • Hypertension*
  • Hypertriglyceridemia* / diagnosis
  • Hypertriglyceridemia* / therapy
  • Hypoglycemic Agents / therapeutic use
  • Hypolipidemic Agents / therapeutic use
  • Insulin Resistance*
  • Lipoproteins, HDL / blood
  • Male
  • Obesity / therapy
  • Syndrome
  • Weight Loss


  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Lipoproteins, HDL